Repligen Corp. (NASDAQ:RGEN) CEO Anthony Hunt sold 5,000 shares of the stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $33.12, for a total transaction of $165,600.00. Following the sale, the chief executive officer now owns 68,342 shares of the company’s stock, valued at approximately $2,263,487.04. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Shares of Repligen Corp. (NASDAQ:RGEN) opened at 33.42 on Wednesday. The firm has a market cap of $1.13 billion, a PE ratio of 161.45 and a beta of 1.63. The company’s 50 day moving average is $30.24 and its 200-day moving average is $28.71. Repligen Corp. has a 12 month low of $20.07 and a 12 month high of $34.06.

Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, November 3rd. The company reported $0.08 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.08. The company had revenue of $24.70 million for the quarter, compared to analyst estimates of $24.39 million. Repligen Corp. had a net margin of 6.89% and a return on equity of 10.16%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.08 earnings per share. Equities research analysts predict that Repligen Corp. will post $0.45 EPS for the current year.

WARNING: “Repligen Corp. (RGEN) CEO Anthony Hunt Sells 5,000 Shares” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and reposted in violation of US and international trademark & copyright laws. The correct version of this story can be read at http://www.dailypolitical.com/2016/11/30/repligen-corp-rgen-ceo-anthony-hunt-sells-5000-shares.html.

Separately, Zacks Investment Research upgraded shares of Repligen Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th.

Several institutional investors have recently modified their holdings of the stock. Municipal Employees Retirement System of Michigan raised its position in shares of Repligen Corp. by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 7,460 shares of the company’s stock valued at $225,000 after buying an additional 120 shares during the last quarter. Aperio Group LLC raised its position in shares of Repligen Corp. by 1.9% in the third quarter. Aperio Group LLC now owns 8,200 shares of the company’s stock valued at $248,000 after buying an additional 151 shares during the last quarter. PineBridge Investments L.P. raised its position in shares of Repligen Corp. by 5.7% in the second quarter. PineBridge Investments L.P. now owns 4,266 shares of the company’s stock valued at $117,000 after buying an additional 230 shares during the last quarter. American International Group Inc. raised its position in shares of Repligen Corp. by 1.2% in the second quarter. American International Group Inc. now owns 25,105 shares of the company’s stock valued at $687,000 after buying an additional 295 shares during the last quarter. Finally, Suntrust Banks Inc. raised its position in shares of Repligen Corp. by 3.4% in the third quarter. Suntrust Banks Inc. now owns 12,532 shares of the company’s stock valued at $377,000 after buying an additional 407 shares during the last quarter. 94.43% of the stock is currently owned by institutional investors.

Repligen Corp. Company Profile

Repligen Corporation is a bioprocessing company. The Company is focused on the development, production and commercialization of products used in the process of manufacturing biologic drugs (bioprocessing). The Company is a manufacturer of both native and recombinant forms of Protein A, critical reagents used in biomanufacturing to separate and purify monoclonal antibodies, a type of biologic drug.

5 Day Chart for NASDAQ:RGEN

Receive News & Ratings for Repligen Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corp. and related companies with MarketBeat.com's FREE daily email newsletter.